Company Plans to Cut Workforce by Approximately 50% to Optimize Costs
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 13 2026
0mins
Should l Buy CLGN?
The company said, "To ensure we are well positioned for the road ahead, we have updated our expense forecast and are implementing a cost-reduction and workforce optimization plan. As part of this initiative, we are in the process of reducing our workforce by approximately 50%. We are confident these measures will sharpen our focus and believe this will extend our cash runway into Q4 2026, positioning us to achieve our next key milestones from a position of strength. As we move forward, we are building on a strong foundation, with three core programs - regenerative dermal and soft tissue fillers, regenerative breast implants, and rhCollagen bioinks for 3D bioprinting of tissues and organs - that we believe have the potential to drive meaningful growth and value creation in the years ahead."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLGN
About CLGN
CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CollPlant Ends AbbVie Partnership, Eyes New Opportunities Ahead
- Partnership Termination: CollPlant announced the termination of its development agreement with AbbVie, viewing this end as a new beginning, as the company actively seeks new strategic partners in the medical aesthetics market for 2026.
- Cost Optimization Plan: To ensure future positioning, CollPlant is implementing a cost-reduction and workforce optimization plan, aiming to reduce its workforce by approximately 50%, which is expected to extend the company's cash runway into Q4 2026, thereby laying the groundwork for achieving key milestones.
- Technological Innovation: CollPlant is developing photocurable dermal filler technology designed to create a stable crosslinked scaffold through light activation, with plans to initiate clinical trials within two years, aiming to commercialize next-generation regenerative aesthetic solutions.
- BioInk Product Line: CollPlant launched BioFlex, a kit designed for 3D bioprinting applications using plant-derived recombinant human collagen, providing a sustainable alternative for research, and is expected to attract collaborations with leading research institutions to expand market influence.
See More
CollPlant Biotechnologies Reports FY 2025 Financial Results
- Financial Performance: CollPlant Biotechnologies reported a FY 2025 non-GAAP EPS of -$0.83, despite a remarkable 355.8% year-over-year revenue increase to $2.37 million, indicating potential in revenue growth but ongoing profitability challenges.
- Cash Flow Status: As of December 31, 2025, the company had $5.6 million in cash and cash equivalents, with cash used in operating activities reduced to $9.4 million from $14.1 million in 2024, suggesting some progress in cost management.
- Market Warning: CollPlant received a Nasdaq notice regarding a minimum bid price of $1, which poses a threat to its stock price stability, potentially affecting investor confidence and limiting future financing capabilities.
- Quant Rating: Seeking Alpha's Quant Rating on CollPlant reflects a cautious market outlook on its future performance, highlighting investor concerns regarding the company's long-term profitability.
See More
CollPlant Reports 2025 Financial Results and Corporate Updates
- Financial Performance Boost: CollPlant's GAAP revenue for 2025 reached $2.4 million, significantly up from $515,000 in 2024, primarily driven by a $2 million milestone payment from AbbVie, highlighting the company's commercial potential in regenerative medicine.
- Product Line Expansion: The company successfully broadened its distribution network in North America through a new partnership with a U.S. logistics center, enhancing market coverage for its rhCollagen and BioInk product lines, which is expected to further drive sales growth.
- Technological Innovation: Researchers at Mayo Clinic developed the first fully humanized 3D bioprinted skin model using CollPlant's rhCollagen, providing a sustainable alternative to animal testing, which is anticipated to drive market opportunities in bioprinting and tissue engineering, with a market size of approximately $100 million projected to grow over 10% annually.
- Intellectual Property Enhancement: CollPlant secured new patents related to its photocurable dermal filler technology in the U.S. and South Korea, further strengthening its intellectual property position in the aesthetic medicine market, which is expected to provide robust legal protection for future commercial applications.
See More
CollPlant Faces Nasdaq Delisting Risk Due to Low Share Price
- Nasdaq Compliance Notice: On March 23, 2026, CollPlant received a written notice from Nasdaq indicating non-compliance with Listing Rule 5550(a)(2) due to its ordinary shares closing bid price being below $1.00 for the last 30 consecutive business days, which poses a risk of delisting.
- Compliance Period: Under Nasdaq Rule 5810(c)(3)(A), the company has been granted a 180-calendar day compliance period until September 21, 2026, to regain compliance by achieving a closing bid price of at least $1.00 for 10 consecutive business days.
- Remedial Actions: If compliance is not regained within the initial period, the company may qualify for a second 180-day compliance period, but must meet other listing standards and may need to implement a reverse stock split to address the price deficiency.
- Market Monitoring Plan: CollPlant intends to monitor the closing bid price of its ordinary shares during the compliance period and will consider available options to cure the deficiency and regain compliance to continue trading on the Nasdaq Capital Market.
See More
CollPlant Receives Nasdaq Warning on Share Price
- Nasdaq Warning: CollPlant Biotechnologies received a written notice from Nasdaq indicating that its ordinary shares have closed below $1.00 for 30 consecutive business days, failing to meet Nasdaq Listing Rule 5550((a))(2), which could negatively impact the company's market perception and investor confidence.
- Compliance Period: The company has been granted a 180-day grace period until September 21, 2026, to regain compliance by achieving a closing bid of at least $1.00 for 10 consecutive business days, providing time for the company to strategize its response.
- Trading Status: Despite the warning, CollPlant's shares will continue to trade on Nasdaq, indicating that the company has an opportunity to improve its stock performance through proactive measures, maintaining market activity.
- Potential Measures: CollPlant is evaluating options, including a potential reverse stock split, to address the deficiency in share price, a strategy that may impact shareholder structure and future financing capabilities.
See More
CollPlant to Report 2025 Financial Results on March 26, 2026
- Earnings Report Schedule: CollPlant Biotechnologies plans to release its financial results for the fiscal year 2025 on March 26, 2026, before the U.S. market opens, which is expected to provide crucial insights into the company's financial health and may influence its stock performance.
- Technological Innovation Focus: CollPlant specializes in regenerative and aesthetic products based on non-animal-derived collagen, utilizing its proprietary plant-based genetic engineering technology to produce recombinant human collagen, aiming to meet diverse needs in tissue repair and aesthetics while driving technological advancements in the industry.
- Strategic Partnership: In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, a leader in the dermal filler market, which not only strengthens CollPlant's market position but also lays the groundwork for future revenue growth.
- Company Vision: CollPlant is committed to advancing the manufacturing of tissues and organs through 3D bioprinting technology, marking a new era of medical solutions that is expected to have a profound impact on the field of regenerative medicine and enhance the company's competitiveness in the industry.
See More
CollPlant Ends AbbVie Partnership, Eyes New Opportunities Ahead
- Partnership Termination: CollPlant announced the termination of its development agreement with AbbVie, viewing this end as a new beginning, as the company actively seeks new strategic partners in the medical aesthetics market for 2026.
- Cost Optimization Plan: To ensure future positioning, CollPlant is implementing a cost-reduction and workforce optimization plan, aiming to reduce its workforce by approximately 50%, which is expected to extend the company's cash runway into Q4 2026, thereby laying the groundwork for achieving key milestones.
- Technological Innovation: CollPlant is developing photocurable dermal filler technology designed to create a stable crosslinked scaffold through light activation, with plans to initiate clinical trials within two years, aiming to commercialize next-generation regenerative aesthetic solutions.
- BioInk Product Line: CollPlant launched BioFlex, a kit designed for 3D bioprinting applications using plant-derived recombinant human collagen, providing a sustainable alternative for research, and is expected to attract collaborations with leading research institutions to expand market influence.
See More
CollPlant Biotechnologies Reports FY 2025 Financial Results
- Financial Performance: CollPlant Biotechnologies reported a FY 2025 non-GAAP EPS of -$0.83, despite a remarkable 355.8% year-over-year revenue increase to $2.37 million, indicating potential in revenue growth but ongoing profitability challenges.
- Cash Flow Status: As of December 31, 2025, the company had $5.6 million in cash and cash equivalents, with cash used in operating activities reduced to $9.4 million from $14.1 million in 2024, suggesting some progress in cost management.
- Market Warning: CollPlant received a Nasdaq notice regarding a minimum bid price of $1, which poses a threat to its stock price stability, potentially affecting investor confidence and limiting future financing capabilities.
- Quant Rating: Seeking Alpha's Quant Rating on CollPlant reflects a cautious market outlook on its future performance, highlighting investor concerns regarding the company's long-term profitability.
See More
CollPlant Reports 2025 Financial Results and Corporate Updates
- Financial Performance Boost: CollPlant's GAAP revenue for 2025 reached $2.4 million, significantly up from $515,000 in 2024, primarily driven by a $2 million milestone payment from AbbVie, highlighting the company's commercial potential in regenerative medicine.
- Product Line Expansion: The company successfully broadened its distribution network in North America through a new partnership with a U.S. logistics center, enhancing market coverage for its rhCollagen and BioInk product lines, which is expected to further drive sales growth.
- Technological Innovation: Researchers at Mayo Clinic developed the first fully humanized 3D bioprinted skin model using CollPlant's rhCollagen, providing a sustainable alternative to animal testing, which is anticipated to drive market opportunities in bioprinting and tissue engineering, with a market size of approximately $100 million projected to grow over 10% annually.
- Intellectual Property Enhancement: CollPlant secured new patents related to its photocurable dermal filler technology in the U.S. and South Korea, further strengthening its intellectual property position in the aesthetic medicine market, which is expected to provide robust legal protection for future commercial applications.
See More
CollPlant Faces Nasdaq Delisting Risk Due to Low Share Price
- Nasdaq Compliance Notice: On March 23, 2026, CollPlant received a written notice from Nasdaq indicating non-compliance with Listing Rule 5550(a)(2) due to its ordinary shares closing bid price being below $1.00 for the last 30 consecutive business days, which poses a risk of delisting.
- Compliance Period: Under Nasdaq Rule 5810(c)(3)(A), the company has been granted a 180-calendar day compliance period until September 21, 2026, to regain compliance by achieving a closing bid price of at least $1.00 for 10 consecutive business days.
- Remedial Actions: If compliance is not regained within the initial period, the company may qualify for a second 180-day compliance period, but must meet other listing standards and may need to implement a reverse stock split to address the price deficiency.
- Market Monitoring Plan: CollPlant intends to monitor the closing bid price of its ordinary shares during the compliance period and will consider available options to cure the deficiency and regain compliance to continue trading on the Nasdaq Capital Market.
See More
CollPlant Receives Nasdaq Warning on Share Price
- Nasdaq Warning: CollPlant Biotechnologies received a written notice from Nasdaq indicating that its ordinary shares have closed below $1.00 for 30 consecutive business days, failing to meet Nasdaq Listing Rule 5550((a))(2), which could negatively impact the company's market perception and investor confidence.
- Compliance Period: The company has been granted a 180-day grace period until September 21, 2026, to regain compliance by achieving a closing bid of at least $1.00 for 10 consecutive business days, providing time for the company to strategize its response.
- Trading Status: Despite the warning, CollPlant's shares will continue to trade on Nasdaq, indicating that the company has an opportunity to improve its stock performance through proactive measures, maintaining market activity.
- Potential Measures: CollPlant is evaluating options, including a potential reverse stock split, to address the deficiency in share price, a strategy that may impact shareholder structure and future financing capabilities.
See More
CollPlant to Report 2025 Financial Results on March 26, 2026
- Earnings Report Schedule: CollPlant Biotechnologies plans to release its financial results for the fiscal year 2025 on March 26, 2026, before the U.S. market opens, which is expected to provide crucial insights into the company's financial health and may influence its stock performance.
- Technological Innovation Focus: CollPlant specializes in regenerative and aesthetic products based on non-animal-derived collagen, utilizing its proprietary plant-based genetic engineering technology to produce recombinant human collagen, aiming to meet diverse needs in tissue repair and aesthetics while driving technological advancements in the industry.
- Strategic Partnership: In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, a leader in the dermal filler market, which not only strengthens CollPlant's market position but also lays the groundwork for future revenue growth.
- Company Vision: CollPlant is committed to advancing the manufacturing of tissues and organs through 3D bioprinting technology, marking a new era of medical solutions that is expected to have a profound impact on the field of regenerative medicine and enhance the company's competitiveness in the industry.
See More
